NAGE Q3 2024 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$423M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+31.2% YoY

Gross Profit

$16M63.5% margin

Operating Income

$2M6.3% margin

Net Income

$2M7.3% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+12.5%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

$3M

Stock-Based Comp.

$735,000

Balance Sheet

Total Assets

$57M

Total Liabilities

$22M

Stockholders' Equity

$34M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$19M	+31.2%
Gross Profit	$16M	$12M	+35.7%
Operating Income	$2M	-$1M	+239.7%
Net Income	$2M	-$959,000	+295.8%